Kontafarma China Sustainability Profile
Kontafarma China, officially known as Kontafarma Limited, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Hong Kong. Founded in 2005, the company has established a strong presence across Asia, focusing on the development and distribution of innovative healthcare solutions. Specialising in prescription medications, over-the-counter products, and health supplements, Kontafarma is recognised for its commitment to quality and efficacy. The company’s unique approach combines advanced research with a deep understanding of local market needs, allowing it to deliver tailored solutions that enhance patient care. With a reputation for excellence, Kontafarma has achieved significant milestones, including strategic partnerships and a growing portfolio of proprietary products. As a trusted name in the industry, Kontafarma continues to strengthen its market position, contributing to the advancement of healthcare in the region.
DitchCarbon Score
How does Kontafarma China's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kontafarma China's score of 27 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kontafarma China's reported carbon emissions
In 2024, Kontafarma China reported total carbon emissions of approximately 1,470,000 kg CO2e, all of which fall under Scope 2 emissions, specifically from purchased electricity. This figure represents a slight increase from 2023, when emissions were about 1,057,000 kg CO2e, also entirely from Scope 2. The company has not disclosed any Scope 1 emissions data for these years. Kontafarma China has set ambitious near-term climate commitments, aiming for significant reductions in both Scope 1 and Scope 2 emissions by 2025. The organisation is dedicated to creating value in the low-carbon transition and achieving sustainable development through continuous emissions and resource consumption reductions. The emissions data for Kontafarma China is cascaded from its parent company, Kontafarma China Holdings Limited, reflecting the corporate family's commitment to climate action. The company is currently classified as a current subsidiary, and its climate initiatives are aligned with broader corporate sustainability goals. Overall, Kontafarma China is actively working towards its climate commitments, focusing on reducing its carbon footprint in the coming years.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,487,000 | 0,000,000 | - | - | - |
| Scope 2 | 3,922,000 | 0,000,000 | - | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000 | - | - |
How Carbon Intensive is Kontafarma China's Industry?
How Carbon Intensive is Kontafarma China's Location?
Kontafarma China's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kontafarma China has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
